Senti Biosciences, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
SNTI Nasdaq 2836 www.sentibio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Senti Biosciences, Inc.

Senti Bio price target raised to $12 from $10 at Chardan - Dec 5th, 2024 12:00 pm
Senti Biosciences Announces New Employment Inducement Grants - Dec 4th, 2024 1:00 am
SNTI Stock Skyrockets on Initial Data From Phase I Cancer Study - Dec 3rd, 2024 3:56 pm
Senti Bio reports positive initial clinical data from Phase 1 trial of SENTI-202 - Dec 3rd, 2024 12:18 pm
Sector Update: Health Care Stocks Slipping Late Afternoon - Dec 2nd, 2024 9:02 pm
Why Is Senti Biosciences Stock Surging Over 400% On Monday? - Dec 2nd, 2024 4:44 pm
Senti Biosciences, Inc. Announces Oversubscribed $37.6 Million Private Placement Equity Financing - Dec 2nd, 2024 12:10 pm
Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI-202, a Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy for the Treatment of Relapsed/Refractory Hematologic Malignancies Including AML - Dec 2nd, 2024 12:02 pm
Senti Bio Appoints Fran Schulz to Board of Directors - Dec 2nd, 2024 12:00 pm
Senti Bio Announces Third Quarter 2024 Results and Recent Pipeline and Corporate Highlights - Nov 14th, 2024 9:05 pm
Senti Bio to Participate in Upcoming Investor Conferences - Sep 3rd, 2024 12:15 pm
Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights - Aug 13th, 2024 8:05 pm
Senti Bio Announces Execution of Grant Award from California Institute for Regenerative Medicines (CIRM) for Clinical Development of SENTI-202 - Aug 5th, 2024 12:05 pm
Senti Bio Announces Reverse Stock Split - Jul 16th, 2024 12:30 pm
Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy - Jul 1st, 2024 12:05 pm
Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia - May 13th, 2024 12:15 pm
Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights - May 9th, 2024 8:05 pm
Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML) - Apr 30th, 2024 12:05 pm
Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights - Mar 21st, 2024 8:05 pm
Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program - Jan 5th, 2024 9:05 pm